Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;26(1):173-182.
doi: 10.1007/s10741-019-09901-2.

Sympathetic activation in congestive heart failure: an updated overview

Guido Grassi  1 , Fosca Quarti-Trevano  2 , Murray D Esler  3
Affiliations
Review

Sympathetic activation in congestive heart failure: an updated overview

Guido Grassi et al. Heart Fail Rev. 2021 Jan.

Abstract

Conclusive evidence demonstrates that the sympathetic nervous system activation is a hallmark of congestive heart failure. This has been shown via a variety of biochemical, neurophysiological, and neuroimaging approaches for studying human sympathetic neural function. The sympathetic activation appears to be an early phenomenon in the clinical course of the disease, closely related to its severity and potentiated by the concomitant presence of other comorbidities, such as obesity, diabetes mellitus, metabolic syndrome, hypertension, and renal failure. The adrenergic overdrive in heart failure is associated with other sympathetic abnormalities, such as the downregulation of beta-adrenergic adrenoreceptors at cardiac level, and exerts unfavorable consequences on the cardiovascular system. These include the endothelial dysfunction, the development of left ventricular hypertrophy, the atherosclerosis development, as well as the generation of atrial and ventricular arrhythmias, and, at very extreme levels of sympathetic activation, the occurrence of microscopic myocardial necrosis. Given the close direct independent relationships detected in heart failure between sympathetic activation and mortality, the adrenergic overdrive has become a target of neuromodulatory therapeutic interventions, which include non-pharmacological, pharmacological, and device-based interventions. For some of these approaches (specifically bilateral renal nerves ablation and carotid baroreceptor stimulation), additional studies are needed to better define their impact on the clinical course of the disease.

Keywords: Baroreceptors; Heart failure; Neuromodulation; Sympathetic nervous system.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Willis T (1664-1964) The anatomy of the brain and nerves, 3rd edn. Feindel W (ed). McGill University Press, Montreal
    1. Heymans CJF, Folkow B (1982) Vasomotor control and regulation of blood pressure. In: Fishman AP, Richards DW (eds) Circulation of the blood. Men and Ideas. American Physiological Society, Bethesda, pp 407–486
    1. Von Euler US (1946) A specific sympathetic ergone in adrenergic nerve fibres (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol Scand 12:73–97
    1. Von Euler US, Hellner S, Purkhold A (1954) Excretion of noradrenaline in the urine in hypertension. Scand J Clin Lab Invest 6:54–59
    1. Grassi G, Esler M (1999) How to assess sympathetic activity in humans. J Hypertens 17:719–734 - PubMed

LinkOut - more resources